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Membrane lipidomics in schizophrenia patients: a
correlational study with clinical and cognitive manifestations
C Tessier1,2, K Sweers3, A Frajerman2, H Bergaoui2, F Ferreri2, C Delva4, N Lapidus5,6, A Lamaziere1,7, JP Roiser8, M De Hert3 and
P Nuss1,2,7
Schizophrenia is a severe mental condition in which several lipid abnormalities—either structural or metabolic—have been
described. We tested the hypothesis that an abnormality in membrane lipid composition may contribute to aberrant dopamine
signaling, and thereby symptoms and cognitive impairment, in schizophrenia (SCZ) patients. Antipsychotic-medicated and clinically
stable SCZ outpatients (n= 74) were compared with matched healthy subjects (HC, n= 40). A lipidomic analysis was performed in
red blood cell (RBC) membranes examining the major phospholipid (PL) classes and their associated fatty acids (FAs). Clinical
manifestations were examined using the positive and negative syndrome scale (PANSS). Cognitive function was assessed using the
Continuous Performance Test, Salience Attribution Test and Wisconsin Card Sorting Test. Sphingomyelin (SM) percentage was the
lipid abnormality most robustly associated with a schizophrenia diagnosis. Two groups of patients were deﬁned. The ﬁrst group
(SCZ c/SM− ) is characterized by a low SM membrane content. In this group, all other PL classes, plasmalogen and key
polyunsaturated FAs known to be involved in brain function, were signiﬁcantly modiﬁed, identifying a very speciﬁc membrane lipid
cluster. The second patient group (SCZ c/SM+) was similar to HCs in terms of RBC membrane SM composition. Compared with SCZ
c/SM+, SCZ c/SM− patients were characterized by signiﬁcantly more severe PANSS total, positive, disorganized/cognitive and
excited psychopathology. Cognitive performance was also signiﬁcantly poorer in this subgroup. These data show that a speciﬁc RBC
membrane lipid cluster is associated with clinical and cognitive manifestations of dopamine dysfunction in schizophrenia patients.
We speculate that this membrane lipid abnormality inﬂuences presynaptic dopamine signaling.
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INTRODUCTION
Schizophrenia is a chronic multifactorial disorder characterized by
a number of symptom dimensions, cognitive abnormalities and
functional impairment. These features are highly variable among
individuals with schizophrenia, resulting in great heterogeneity
in clinical presentation. Several explanatory models have been
proposed to conceptualize the combination of these various
characteristics. To date, none have accounted for the overall
diversity of the observed manifestations, and most of the
proposed models allow only a partial understanding of the
disorder. The lipid hypothesis of schizophrenia of Horrobin1 was
conceived in this framework, proposing to reconcile apparently
heterogeneous schizophrenia features and also suggesting a
biological basis for disease vulnerability.
Today, advances in lipidomics such as high-performance liquid
chromatography, electrospray ionization and mass spectrometry
have contributed to a more in-depth understanding of lipid
physiology and allowed further developments of the original
phospholipid (PL) hypothesis of schizophrenia. Lipids are now
understood as versatile and dynamic regulators of numerous
cellular processes that encompass, among others, signaling,
budding and fusion of vesicles.2 Lipids are also known to move
rapidly in the plane as well as across the bilayer in a dynamic and
highly organized manner, particularly in red blood cell (RBC),3 to
control various cellular activities.4 In this context, the lipid pattern
abnormality in membranes is conceived as a trait or vulnerability
marker associated with the disorder.
The new ﬁeld of neurolipidomics seeks to understand how
dynamic changes in membrane composition regulate brain cell
function. The lipid composition of brain membranes is brain-
region speciﬁc,5 but is also governed by mechanisms that control
the membrane composition in cells throughout the body. Brain
signaling may thus be assessed indirectly via the study of the lipid
composition of membrane in peripheral cells such as RBCs.6–8
Membrane abnormalities in schizophrenia patients were demon-
strated via measurement of the membrane PL ratio,9,10 turnover11
and inner/outer distribution,12 as well as quantiﬁcation and
identiﬁcation of the polyunsaturated fatty acids (PUFAs) from
PL.13
Here, we undertook a lipidomic study of the RBC membrane of
chronic medicated schizophrenia patients to identify abnormal
membrane lipid clusters associated with the disorder, and also to
distinguish patient subgroups. On the basis of studies in lipid-
deprived animals showing that abnormal lipid metabolism is
associated with disrupted dopamine dysfunction,14 we sought to
examine whether speciﬁc membrane lipid clusters are associated
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with dopamine-related symptomatology and cognition in patients
with schizophrenia.
MATERIALS AND METHODS
Study population
The study included 74 antipsychotic-medicated and clinically stable
outpatients with schizophrenia (SCZ, DSM-IV-TR criteria) and not meeting
criteria for another treated DSM-IV axis III disorder. The healthy control (HC)
group was composed of 40 subjects matched for age and education level,
recruited among hospital staff and students with no personal and family
history of psychosis and/or bipolar disorder. In both the groups, exclusion
criteria included cholesterol-lowering treatments and dietary supplemen-
tation with PUFAs. The metabolic syndrome was not an exclusion criterion,
except when it required a pharmacological treatment following a
clinician’s opinion. Cholesterol-lowering medication was an exclusion
criterion because membrane and circulating cholesterol can exchange to
some points and cannot be considered independent compartments in
terms of cholesterol content. Food intake was assessed in patients through
a dietary questionnaire.15 The patients and controls provided written
informed consent in a protocol approved by the Medical Ethics Committee
of the University Psychiatric Centre (EC/UC/(2011-16), Katholieke Universi-
teit Leuven, campus Kortenberg (Belgium)). The demographic and clinical
characteristics of the study samples are summarized in Table 1.
Antipsychotic medication consisted of either typical (haloperidol, chlor-
promazine, ﬂupentixol) or atypical compounds (amisulpride, aripiprazole,
clozapine, olanzapine, quetiapine, sertindole and risperidone).
Clinical and cognitive measures
Patients’ psychopathology, general functioning and cognition were
assessed by a trained nurse. The Positive and Negative Syndrome Scale
(PANSS),16 Global Assessment of Functioning and Clinical Global Impres-
sion scales have been completed. The cognitive tasks were administrated
using a computerized platform. Three tests have been used: AX
Continuous Performance Test (CPT-AX), Salience Attribution Test (SAT)
and Wisconsin Card Sorting Test (WCST).
The CPT-AX is a measure of sustained attention and working memory,
consisting of a series of trials on which a single letter is presented brieﬂy in the
middle of the screen. This version of the test also included different colored
(that is, visually salient) stimuli on 20% of the trials, adding a perceptual
salience component to the test.17 The task was programmed in PXLAB.18
The SAT is a test of reward learning and motivational responding, on
which participants must respond to a target stimulus immediately
preceded by a cue, which signals the probability of gaining a reward,
the magnitude of which is higher for quicker responses.19 The task was
programmed in Cogent, a stimulus presentation toolbox for Matlab.
The WCST is a test evaluating mental ﬂexibility and working memory,20
on which participants must sort cards according to different rules, which
must be learned from feedback and change periodically. We used the
WCST Research Edition Version 2 (http://www.parinc.com).
Biological measures
The lipid composition of the RBC membrane was studied to identify and
measure all major lipid classes: phosphatidylcholine (PC), phosphatidylser-
ine (PS), sphingomyelin (SM), phosphatidylethanolamine (PE), PE plasmalo-
gen and their molecular species. The number of the major molecular
species studied was 45, 18, 23 and 42 for PC, PS, SM and PE, respectively.
PE was further studied as a function of its location in the outer and inner
membrane leaﬂet. Both diacyl phosphatidylethanolamine (DPE) and
monoacyl phosphatidylethanolamine (LPE), which together comprise PE,
were measured on each of the membrane leaﬂet.
The detailed presentation of the blood sample preparation and data
acquisition of phospholipids with liquid chromatography-tandem mass
spectromerty (LC-MS/MS) for complete lipid data analysis is provided in
the Supplementary Methods (Lipid measures). In brief, total lipids were
extracted from the RBC cell membranes based on the methods of Folch
et al.21 Outer leaﬂet and total membrane PE labeling was made using
trinitro-benzylsulfonic acid (Sigma-Aldrich, Saint-Quentin Fallavier, France).
Separation of PL classes were obtained using high-performance liquid
chromatography (HPLC) solvent gradient program and spectrometry
identiﬁcation parameters (Supplementary Tables S-A to D, Supplementary
Methods). The application of HPLC solvent gradient and mass spectrometer
scan functions were controlled by the Analyst Software (AB Sciex, Les Ulis,
France) data system. The samples were analyzed using an electrospray
ionization tandem mass spectrometry (ESI/MS/MS, API3000, TQ, Applied
Biosystems-Sciex, Concord, ON, Canada) either with scan mode or multiple-
reaction monitoring. A comprehensive description of the methodology can
be found in Brugger et al.22 Multiple-reaction monitoring was used to
measure the distribution of DPE and LPE between the two RBC membrane
leaﬂets. The complete lipid data were acquired using Analyst 4.2.2 software.
To identify and quantify spectral peaks, LIMSA software was used.23
Statistical data analysis
The data were analyzed using SAS 9.3. The groups were compared using
t-tests for continuous variables or a non-parametric Mann–Whitney
Wilcoxon test when parametric assumptions were violated (normality
tested with the Kolmogorov–Smirnov test). Categorical data were analyzed
using chi-square tests. Correlations with RBC PLs were investigated using
Table 1. Demographic and clinical data
Characteristics SCZ HC Chi-square Q MWW Z P-value
Mean s.d. Mean s.d.
N 74 40
Gender: male (% of total population) 48 (64.8%) 24 (60%) 0.747 (1 d.o.f.) 0.387
Age (years) 43.8 9.3 42.6 13.2 0.462 0.644
Education level (in % of total) 3.329 (3 d.o.f.) 0.344
Lower High School 3 (4.1%) 1 (2.5%)
High School 39 (53.4%) 15 (37.5%)
College 17 (23.3%) 12 (30.0%)
University 14 (19.2%) 12 (30.0%)
Age of onset (year) 24.6 6.2 —
Duration of illness (years) 22.3 6.4 —
Number of hospitalizations 7.8 5.5 —
Chlorpromazine equivalent (mg) 480.2 383.4 —
CGI (mean) 3.03 0.74 —
GAF (mean) 66.7 8.5 —
PANSS (mean total score) 48.5 16.3 —
Abbreviations: CGI, Clinical Global Impression; d.o.f., degree of freedom; GAF, Global Assessment of Functioning; HC, healthy control; MWW, Mann–Whitney
Wilcoxon test; PANSS, Positive and Negative Syndrome Scale; SCZ, schizophrenia. Comparisons were performed with chi-square tests for categorical data and
Mann–Whitney Wilcoxon tests for quantitative data.
Clinical and cognitive measures in schizophrenia: a lipidomic study
C Tessier et al
2
Translational Psychiatry (2016), 1 – 8
Spearman’s correlation tests. A step-wise logistic multivariate analysis
including PS, SM, PC, PE, external DPE, external LPE and PE plasmalogen
was performed to determine which lipid variables were most reliably
associated with schizophrenia diagnosis. All the tests were two-sided with
a statistical signiﬁcance level set at P = 0.05. For cognitive and clinical data
one-way and two-way analyses of variance with SM group and diagnosis
group as ﬁxed factors and the SM×diagnosis interaction term were
estimated. Box-Cox power transformation of continuous variables was
used to limit departures from normality assumptions. Results are given
with the Fk statistic including the number of degrees of freedom, k.
Multimodality of the SM distribution was tested to assess whether the
distribution was a mixture of normal laws, using a clustering analysis with
bayesian information criterion for information criterion.24
RESULTS
As shown in Table 1, the SCZ and HC groups did not differ in terms
of age, sex and education level.
Membrane lipid composition differs in patients and healthy controls
As shown in Table 2a, a univariate analysis of the RBC lipids
identiﬁed signiﬁcantly lower SM percentage in the SCZ group
compared with the HC group (27.38 vs 30.59%), along with a
concomitant higher PS percentage (8.73 vs 6.64%).
Decreased membrane sphingomyelin percentage allowed
distinguish four study populations
In a multiple logistic regression analysis using membrane PL
values to predict schizophrenia diagnosis, only SM was selected
(odds-ratio estimate of 0.833 with 95% Wald Conﬁdence
Limits (0.744–0.933), P = 0.0003), conﬁrming its strong association
with diagnosis. The SM percentage appeared to follow a
‘bimodal’ distribution, that is a mixture of two normal laws with
means 23.2 and 22.5% and same variance 5.4. A threshold value
of SM percentage was then determined to classify individuals
according to mean SM percentage value: (1) those in the range
of HCs; and (2) those below this value. A receiver operating
characteristic curve identiﬁed an SM cutoff of 28.58 (mean %)
to maximize the Youden index. Only 22.5% of the HCs
exhibited an ‘abnormal’ SM percentage while this was identiﬁed
in 55.4% of the schizophrenia patients (chi-square Q= 10.12,
P= 0.0015).
Two clusters of membrane lipid constitutions can be described,
identifying two population groups. The group named ‘cluster/
SM− ’ (c/SM− ) is constituted of individuals whose RBC membrane
comprises a SM mean percentage below 28.58. By contrast, the c/
SM+ group has a mean SM percentage above 28.58 (in the range
of the majority of HCs). Four populations can thus be distin-
guished among the study participants: SCZ c/SM− (n= 41), SCZ c/
SM+ (n= 33), HC c/SM− (n= 9) and HC c/SM+ (n= 31). These four
groups are represented on Figure 1.
For biophysical and biological reasons, an isolated decrease of a
membrane PL is not possible without complex and compensatory
changes in the ratio of the other membrane containing lipids.
Thus, SM status cannot be conceived of in isolation, but
considered as a marker of a broader membrane lipid dysfunction.
Compared with their c/SM+ counterparts, each of the c/SM−
patient and HC subgroups exhibit a different cluster of compen-
satory lipids (Table 2b).
Table 2. Phospholipid data from schizophrenia patients and healthy controls
a Total population SCZ (n= 74) HC (n=40) MWW Z P-value
Phospholipid Mean (%) s.d. Mean (%) s.d.
PE 22.40 7.15 19.81 8.38 1.59 0.112
PC 41.49 6.03 42.96 6.06 1.12 0.263
SM 27.38 4.51 30.59 3.76 3.35 0.001
PS 8.73 3.31 6.64 2.12 3.33 0.001
b SCZ (n= 74) P-value HC (n= 40) P-value
Subgroups c/SM− (n= 41) c/SM+ (n=33) c/SM− (n=9) c/SM+ (n= 31)
Phospholipid Mean (%) s.d. Mean (%) s.d. Mean (%) s.d. Mean (%) s.d.
PE 27.12 4.23 16.53 5.48 o0.0001 28.61 8.86 31.51 5.74 0.2570
PC 38.64 5.07 45.04 5.24 o0.0001 36.27 3.63 44.90 5.18 0.0003
SM 23.92 2.69 31.66 1.76 o0.0001 23.92 2.69 31.66 1.76 o0.0001
PS 10.31 3.44 6.77 1.72 o0.0001 7.42 2.40 6.42 2.01 0.2065
Plasmalogen PE 5.34 0.76 6.53 0.17 o0.0001 5.76 0.72 6.89 1.30 0.0121
Outer/Inner leaﬂet PE
Outer PE (DPE+LPE) 6.62 2.17 6.57 2.28 0.9653 6.12 1.81 6.88 3.04 0.7955
DPE 4.94 1.36 4.18 1.32 0.0120 4.25 1.31 4.16 1.67 0.4761
LPE 1.68 1.47 2.39 1.20 0.0007 1.87 0.81 2.73 1.51 0.1450
Inner PE (DPE+LPE) 26.40 5.11 27.84 5.20 0.1919 24.30 5.74 26.38 6.82 0.4563
DPE 22.16 5.17 19.18 4.24 0.0322 19.57 5.35 20.43 5.67 0.9226
LPE 4.24 2.55 8.66 4.18 o0.0001 4.72 1.64 5.95 2.16 0.1363
Abbreviations: DPE, diacyl phosphatidylethanolamine; LPE, monoacyl phosphatidylethanolamine; PC phosphatidylcholine; PE, phosphatidylethanolamine;
PS, phosphatidylserine; SM, sphingomyelin. The section (a) shows the mean ratio for the major phospholipid (PL) classes from RBC membranes in
schizophrenia patients (SCZ) and healthy controls (HC). Section (b) indicates the PL mean percentage in schizophrenia and healthy controls for each SM
subgroup. P-values are derived from the non-parametric Mann–Whitney Wilcoxon (MWW Z) test. Signiﬁcant ﬁndings are in bold.
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Membrane lipid composition and distribution differs between
c/SM+ and c/SM− patient populations
As mentioned above, in the c/SM− patient subgroup, signiﬁcant
concomitant decreases in PC and PE plasmalogen, along with
signiﬁcant increases in PS and PE percentages, were observed
(Table 2b). These results indicate a very different RBC membrane
lipid composition in the c/SM− and c/SM+ patients. The PE
percentages were further characterized as a function of the
location of PE in the membrane leaﬂet (inner- vs outer-located PE).
Compared with the c/SM+ subgroup, c/SM− patients also differed
in DPE/LPE distribution. The c/SM− subgroup exhibited a
signiﬁcant increase in DPE (both external and internal) and a
decrease in LPE (both external and internal; Table 2b).
In addition, key PUFAs known to be modiﬁed in membranes in
schizophrenia patients were compared between the c/SM− and
c/SM+ patients. The molecular species comprising either one or
two of the following PUFAs: linoleic acid (C18:2 n-6), arachidonic
acid (C20:4 n-6), docosapentaenoic acid (C22:5, n-3) and
docosahexaenoic acid (C22:6 n-3) were examined. A signiﬁcant
difference in these molecular species percentage was observed
between the two patient subgroups (Supplementary Table S1,
Supplementary Results). This difference was most pronounced for
the PE molecular species. The PUFA molecular species proﬁle for
LPE and DPE also differed signiﬁcantly in terms of their outer/inner
membrane leaﬂet distribution.
Importantly, the c/SM+ and c/SM− SCZ subgroups did not
differ in age, gender, education level, age of onset, type or disease
duration (Table 4), or amount of antipsychotic medication
(calculated using the chlorpromazine equivalence measure from
Danivas et al.25).
The membrane lipid cluster is not identical in c/SM− patients and
controls
The compensatory lipid changes associated with the low SM
subgroups are population-speciﬁc with the c/SM− patients
deprived in PE and enriched in PS relative to the c/SM− HCs.
Further, the molecular species also differed among the c/SM− SCZ/
HC subgroups in terms of total membrane content and asymme-
trical distribution (Supplementary Table S2, Supplementary Results).
Cognitive measurements
As shown in Table 3, compared with the number of subjects for
which lipid and clinical data were available, the number of
SM- (n=41)
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Figure 1. Distribution of the schizophrenia (SCZ) and healthy control
(HC) samples as a function of their mean SM percentage content
in the RBC membrane. PL, phospholipid; RBC, red blood cell;
SM, sphingomyelin.
Table 3. Cognitive data from schizophrenia and healthy control SM subgroups
SCZ F1 P-value HC F1 P-value
c/SM− c/SM+ c/SM− c/SM+
Mean s.d. Mean s.d. Mean s.d. Mean s.d.
CPT-AX (n=36) (n= 28) (n= 7) (n= 29)
Hit rate 85.71 23.41 78.57 28.24 0.729 0.396 98.98 2.7 95.32 7.7 1.115 0.299
Reaction time mean 498.58 101.4 584.41 167.54 4.943 0.030 444.3 62.5 469.45 79.78 1.138 0.294
False alarm 9.08 12.86 6.73 13.85 4.59 0.036 5.49 3.06 5.36 8.63 0.653 0.425
SAT1 (n=26) (n= 21) (n= 7) (n= 26)
Response time mean 350.8 88.3 349.43 94.89 0.01 0.922 313.61 29.5 299.23 58.45 1.32 0.259
Imp Adap Sal 8.83 42.63 1.83 58.55 0.224 0.638 28.58 20.12 13.11 32.82 1.393 0.247
Imp Aber Sal 31.17 22.56 22.06 21.19 2.787 0.102 29.71 20.82 22.31 17.86 1.573 0.455
Exp Adap Sal 1.25 28.86 28.33 31.79 10.02 0.003 46.07 28.68 35.1 29.03 0.798 0.379
Exp Aber Sal 6.83 7.47 7.86 14.02 1.758 0.192 8.21 7.03 6.63 8.48 0.487 0.490
Money 853.77 329.93 792.05 364.02 0.466 0.498 1004.7 287.22 909.19 313.7 0.546 0.466
WCST (n=22) (n= 12) (n= 5) (n= 19)
Trials 106.45 23.09 89.58 21.25 4.242 0.048 72.8 6.98 86.68 17.11 4.644 0.042
Correct responses 64.05 16.02 69.42 9.14 0.685 0.414 65.2 3.96 70.11 6.53 2.358 0.139
Errors 42.41 31.28 20.17 19.05 5.636 0.024 7.6 3.29 16.58 11.12 8.648 0.007
Pers responses 23.95 21.7 12.08 16.02 6.781 0.014 4.4 1.67 9.21 7.82 3.604 0.071
Pers errors 21 17.55 11.08 13.71 6.524 0.016 4.4 1.67 8.47 6.83 3.588 0.071
Non pers errors 21.41 18.39 9.08 6.08 4.86 0.035 3.2 2.17 8.11 5.32 11.28 0.003
Abbreviations: CPT-AX, Continuous Performance Task AX; Exp aber sal, explicit aberrant salience; Exp adap sal, explicit adaptive salience; HC, healthy control;
Imp aber sal, implicit aberrant salience; Imp adap sal, implicit adaptive salience; Non pers errors, non-perseverative errors; Pers errors, perseverative errors; Pers
responses, perseverative response; SAT, salience attribution test; SCZ, schizophrenia; SM, sphingomyelin; WCST, Wisconsin Card Sorting Test. P-values are
derived from one-way analysis of variance model on power-transformed data. Signiﬁcant ﬁndings are in bold.
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individuals able to perform the cognitive tasks was lower and
variable as a function of the speciﬁc test, thus reducing the
statistical power of these comparisons. Despite this, highly
signiﬁcant results are observed for some cognitive tasks as a
function of SM status.
CPT-AX test
The mean scores for hit rate and reaction time differed
signiﬁcantly between the SCZ and HC groups (Supplementary
Table S3, Supplementary Results). As shown in Table 3, among the
SCZ patients, the c/SM− subjects had shorter mean reaction times
and higher false alarm scores relative to the c/SM+ subjects.
However, the interactions between SM status and diagnostic
group were nonsigniﬁcant for both of these variables.
SAT (ﬁrst block data only)
The scores for mean response time and explicit adaptive
salience differed signiﬁcantly between the SCZ and HC groups
(Supplementary Table S3, Supplementary Results). Among the SCZ
patients, the c/SM− subjects had lower explicit adaptive salience
scores relative to the c/SM+ subjects (Table 3), and the interaction
between SM status and diagnostic group was signiﬁcant.
Notably, only half (n= 12/26) of the c/SM− SCZ patients that
completed the ﬁrst SAT block were able to continue to the second
block, whereas all of the c/SM+ subgroup (n = 21) completed both
blocks, indicating a poorer capacity to be involved in extended
cognitive testing for the c/SM− patient subgroup.
WCST test
The mean scores for trials, errors, perseverative responses,
perseverative errors and non-perseverative errors were signiﬁ-
cantly higher (worse) in SCZ compared with HC (Supplementary
Table S3, Supplementary Results).
Among the SCZ patients, the c/SM− subjects had poorer
performance with signiﬁcantly more trials, errors, perseverative
responses, perseverative errors and non-perseverative errors
(Table 3). Interestingly, SM status was also associated with trials,
errors and non-perseverative errors in the HC group, but in the
opposite direction, with more errors in the c/SM+ group. There
were signiﬁcant interactions between SM status and diagnostic
group for all these variables.
Summary
On all the three cognitive tests, the SCZ patients performed worse
overall than the HCs, but this difference was largely driven by the
c/SM− subgroup of patients. However, among the HCs, SM status
was not associated with impaired cognitive performance.
Supplementary Table S4 (Supplementary Results) shows that
most of the cognitive scores were worse in the c/SM− patients
compared with the c/SM− HC, whereas the c/SM+ HC and SCZ
subgroups scored similarly on many of the variables (data
presented in Table 3, analyses not shown).
Clinical measures
The PANSS scale scores were compared between the c/SM− and
c/SM+ patients (Table 4). PANSS total, positive and general
psychopathology scores were signiﬁcantly higher in the c/SM−
compared with the c/SM+ subgroup. The c/SM− patients scored
also signiﬁcantly higher on the positive, disorganized/cognitive
and excited subscales of the ﬁve dimensional segmentation of the
PANSS, with a trend on the anxiety/depression subscale.26 No
differences were observed between the c/SM subgroups for the
PANSS negative subscale. Of interest, there were twice as many
severe patients (assessed by a PANSS total cutoff of 45) in the
c/SM− group compared with the c/SM+ group.
The more severe WCST impairment in the c/SM− sample
is unlikely to be explained by higher PANSS scores: after
adjusting for the PANSS total score (Supplementary Table S5,
Supplementary Results), SM status remained associated with
trials, errors, perseverative responses, perseverative errors and
non-perseverative errors.
DISCUSSION
Consistent with the existing literature, the present study demon-
strated that the RBC membrane PL composition differs between
stabilized medicated schizophrenia individuals and matched HCs.
Two membrane lipid clusters that aggregate with either low (c/
SM− ) or normal (c/SM+) membrane SM content allowed the
identiﬁcation of two groups of patients distinguishable by the
ratio of all membrane PLs, inner/outer PE distribution and fatty-
acid composition. Compared with the c/SM+ patients, the c/SM−
SCZ subjects are characterized by signiﬁcantly more severe
psychopathology and impaired cognitive performance.
Table 4. Psychopathology scores in both schizophrenia SM
subgroups
SCZ P-value
c/SM− (n= 41) c/SM+ (n= 33)
Mean s.d. Mean s.d.
PANSS
Total 53.32 18.45 42.42 10.78 0.010
Positive 11.61 4.86 9.00 2.88 0.014
Negative 14.71 6.60 12.36 4.84 0.149
General 27.00 9.72 21.06 5.68 0.008
PANSS (5 factors)
Positive 10.41 5.09 7.48 2.09 0.009
Negative 16.76 8.18 13.36 5.08 0.151
Cognitive/
disorganized
11.44 4.05 9.52 2.56 0.041
Excited 5.20 2.42 4.30 0.81 0.038
Anxiety/
depression
9.51 3.70 7.76 2.61 0.060
CGI 3.10 0.83 2.94 0.61 0.292
GAF 66.10 9.32 67.42 7.36 0.675
Age (years) 43.39 8.34 44.31 10.47 0.334
Gender: male
(% of total
population)
28 (70.0%) 22 (66.7%) 1
Age of onset (year) 24.59 5.75 24.64 6.89 0.838
Education level (%) 0.397
Lower High School 2 (5.0%) 1 (3.0%)
High School 24 (60.0%) 15 (45.4%)
College 9 (22.5%) 8 (24.2%)
University 5 (22.4%) 9 (27.3%)
Chlorpromazine
equivalent (mg)
464.6 350 529.5 426 0.474
Disease duration
(years)
18.18 6.82 20.34 8.95 0.448
Abbreviations: CGI, Clinical Global Impression; GAF, Global Assessment of
Functioning; PANSS, Positive and Negative Syndrome Scale; SCZ, schizo-
phrenia; SM, sphingomyelin. P-values are derived from one-way analysis of
variance model the non-parametric Mann–Whitney Wilcoxon (MWW Z) test.
Signiﬁcant ﬁndings are in bold.
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Lipid data
As far as we know, our study is ﬁrst in identifying the four most
important PL classes using LC-MS/MS. In addition, while in other
studies, the total fatty-acid content was measured irrespective of
their PL origin, here the PL molecular species could be identiﬁed in
an individualized basis for each of them. The pattern of membrane
PL alteration in schizophrenia noted in previous studies is
comparable with the data presented here. Signiﬁcantly lower
quantities of PE and PC,27 as well as SM28 were found in post-
mortem brain tissues from patients with schizophrenia. In the
present study, an overall increase of PE was observed. However,
our results showing a signiﬁcant decrease in RBC membrane mean
SM percentage are in agreement with another post-mortem study
showing a decreased SM and increased PS.28 In particular, the
decreased SM percentage observed in the c/SM− patients is
consistent with data showing a myelin sheath alteration in
schizophrenia as evidenced by imaging and post-mortem
studies.29,30
Like many other lipids, SM participates in signaling via its
transmutation into bioactive molecules or indirectly by biophysical
changes in the synapse. At the plasma membrane level, the
concentration of SM can be regulated by multiple enzymes. In
particular, a sphingomyelinase/sphingomyelin synthase system is
involved that controls the membrane levels of both SM and
ceramide. These lipids can also be metabolized to other bioactive
sphingolipids.31 SM is a key PL involved in membrane micro-
domain formation via its aggregation with cholesterol allowing
membrane lipid partition.32 These SM-enriched domains, called
rafts, are involved in the compartmentalization of cellular
processes and also serve as platforms for many cellular signaling
activities33 in which budding and fusion of vesicles are involved.34
The total membrane FA content in schizophrenia patients has
also been investigated previously. In particular, Bentsen et al.35
were able to demonstrate a very highly signiﬁcant bimodal
distribution of PUFA among patients, mirroring the present results
but on total membrane PUFAs. In line with most prior results,13
our study identiﬁed signiﬁcant differences in PUFA content in the
molecular species of PC, PS and PE known to be key for PUFA
content.36 Compared with the c/SM+ subgroup, the c/SM−
patients signiﬁcantly differed in the content of PUFA molecular
species. The speciﬁc inner/outer distribution and FA composition
of DPE and LPE observed for each of the SM groups is in
accordance with the assumption that the membrane homeostasis
of these two populations differs not only in composition but also
distribution. This also conﬁrms our previous ﬁnding showing an
abnormal inner/outer distribution of PE in a subgroup of
schizophrenia patients.12
A dysfunctional plasmalogen dynamic in the plasma and
platelets of schizophrenia patients has been described for the
PE plasmalogens37 and was interpreted as an indirect marker of
increased oxidative stress in these patients.38 In line with these
results, we identiﬁed a signiﬁcant decrease in PE plasmalogen in
the c/SM− subgroup, which was also characterized by more
severe clinical and cognitive features. In this subgroup, the
plasmalogen decrease was associated with a PE increase. This
modiﬁcation is in agreement with a plasmalogen-deprived animal
model, in which a compensatory increase in PE was described,
which presumably occurs to maintain the total membrane amount
of PE/PE plasmalogens.39
Several human studies in schizophrenia and animal models40
have emphasized the role of antipsychotic medication in relation
to the membrane PL abnormalities observed in schizophrenia
patients. A correcting effect of antipsychotic compounds on the
membrane lipid composition has been described41 involving
several mechanisms.42,43 In the present study, all patients were
chronically treated by antipsychotics with no differences in
between SM subgroups in terms of typical/atypical ratio and
medication daily dosage. The difference of membrane lipid
composition observed between the SM subgroups is thus unlikely
to be related to the type or dose of the prescribed antipsychotic
treatment.
Membrane lipid composition, psychopathology and cognitive
performance
PANSS scores. Total, positive, disorganized/cognitive as well as
excited PANSS scores were signiﬁcantly higher in the c/SM−
compared with the c/SM+ patients. Such an effect of PL
composition in the RBC membrane has been previously examined
in few studies taking into account the PL12 and PUFA44 content in
the RBC membrane of patients. Low concentrations of arachidonic
acid and docosahexaenoic acid have been described in patients
with predominantly negative symptoms.45,46 In our study, no
differences in the negative subscale scores were observed
between the SM subgroups.
WCST test. In the present study, the membrane lipid content has
been examined in relation to cognitive performance and
compared with data from ultra-high risk individuals,47 as well as
treated and stabilized patients.48 The observed ﬁndings in the c/
SM− patient subgroup, potentially indicate a more severe
impairment of prefrontal cortex function relative to the c/SM+
patient subgroup. Interestingly, a reverse pattern was observed in
HCs, with SM− status being associated with better performance
relative to c/SM+ (Table 3). Animal studies of chronic deﬁciency in
n-3 PUFA support the hypothesis that cognitive impairment
associated with PL/FA membrane changes is caused by a more
active mesolimbic dopamine pathway and a less active mesocor-
tical pathway.49,50 In line with this ﬁnding, we found that the c/
SM− patients, who exhibited a more pronounced PUFA dysfunc-
tion, manifested both more positive symptoms and WCST deﬁcits
relative to the c/SM+ patients.
SAT test
The dopamine dysregulation described in patients with schizo-
phrenia is thought to be reﬂected in aberrant reward processing.51
In the present study, SAT scores differed between the SM patient
subgroups, with the c/SM− patients having lower explicit
adaptive salience. Consistent with our results, a study aiming to
examine the extent to which some psychotic symptoms reﬂect
aberrant salience, Roiser et al.19 demonstrated that patients with
ﬁrst episode psychosis exhibited reduced explicit adaptive
salience relative to controls, which has been replicated
independently.52 The results presented here suggest that PL
abnormalities may contribute to this disrupted reward learning.
However, implicit aberrant salience scores were not different
between the SM patient subgroups in the present study.
CPT-AX test
Intact prefrontal processing is needed to perform the CPT-AX
test.53,54 In the present study, surprisingly, the c/SM− patients had
shorter reaction times compared with the c/SM+ patients. One
interpretation is that in the c/SM− patients, a more potent effect
of the salient stimuli enabled them to perform the task better
compared with the c/SM+ subgroup. Another explanation is that
the c/SM− group responded faster because they were less
concerned about making errors, in other words adopting a more
impulsive response style (a speed-accuracy trade-off). This latter
interpretation is supported by a concomitant increase in the
number of false alarms committed compared with the c/SM+
patients, also indicative of poorer prefrontal function. That said, it
should be noted that the diagnostic group-by-SM status interac-
tions were nonsigniﬁcant for these variables, which lessens
support for these interpretations
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More pronounced dopamine dysfunction in c/SM− schizophrenia
individuals?
The differences between patients and HCs on all the three
cognitive tests were largely driven by the c/SM− subgroup. In
addition, c/SM− status was associated with more severe PANSS
total and positive scores. We speculate that these results have
some connection with dopamine dysfunction in c/SM− relative
to c/SM+ patients. Indeed more severe positive symptoms,55
disorganization56 and cognitive impairment57,58 have been shown
to be associated with dopamine dysregulation. Our data also
consistent with animal models of chronic dietary n-3 PUFA
deﬁciency59 suggest that the c/SM− patients exhibit more severe
dopamine dysfunction in both the striatum and the prefrontal
cortex compared with the c/SM+ individuals.
CONCLUSION
We found evidence that a speciﬁc RBC membrane lipid cluster was
associated with differences in dopamine-related clinical and
cognitive manifestations in schizophrenia patients. No other
studied clinical or treatment variables could account for these
differences. We hypothesize that the difference in clinical and
cognitive manifestations between the two SM patient groups can,
in part, be explained by differences in presynaptic dopamine
release as converging evidence indicates such dysfunction in
schizophrenia.60–62
Nonetheless, this study does have some limitations. In
particular, fewer patients underwent the cognitive tests compared
with the number of those included in the membrane lipid study,
and the cognitive tests we used are only indirectly related to
dopamine dysfunction. A direct measure of dopamine release
would provide more convincing evidence that membrane lipid
content affects dopamine bioavailability in schizophrenia patients.
In addition, our ﬁnding cannot be generalized to acute and/or low
functioning patients. Furthermore, general conditions that parti-
cipate in the lipid bioavailability such as gut malabsorption, in
particular inﬂammatory bowel status, biliary acid turnover, and
non-celiac and celiac gluten sensitivity have not been addressed
in the present study.
Structural lipid biomarkers are a rapidly evolving ﬁeld, in
particular for neuropsychiatric disorders where even subtle
perturbations in the lipid content of neurons and myelin can
disrupt their function. Considerable further investigation is
needed, including the validation of these ﬁndings in other patient
populations with brain imaging to appraise dopamine dysfunc-
tion. Further questions such as the therapeutic effect of a
membrane lipid content-adjusted PUFA supplementation or the
identiﬁcation of genetic and morphologic differences between
various membrane lipid endophenotypes also represent exciting
areas for further research.
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